Ikesaka Rick, Delluc Aurélien, Le Gal Grégoire, Carrier Marc
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Département de Médecine Interne, EA3878, University of Brest, Brest, France.
Thromb Res. 2014 Apr;133(4):682-7. doi: 10.1016/j.thromres.2014.01.021. Epub 2014 Jan 23.
The bariatric surgical population is a particularly high risk population for VTE. It is unclear if standard (i.e. non-adjusted) thromboprophylaxis doses of low-molecular weight or unfractionated heparin provide adequate protection for obese patients undergoing bariatric surgery, or if higher doses are required. We sought to determine whether a weight based thromboprophylactic dosing regimen is safe and effective in the post-operative period for obese patients undergoing bariatric surgery.
A systematic literature search strategy was conducted using MEDLINE, EMBASE, the Cochrane Register of Controlled Trials and all EBM Reviews. Pooled proportions for the different outcomes were calculated.
A total of 6 studies (1 RCT, 4 cohort studies and one quasi experimental trial) containing 1,858 patients were include in the systematic review. Post bariatric surgery patients receiving weight-adjusted prophylactic doses of heparin products, had an in hospital rate of VTE of 0.54% (95% CI: 0.2 to 1.0%) compared to 2.0% (95% CI: 0.1 to 6.4%) for those that did not weight adjust doses. Rates of major bleeding were similar for both groups: 1.6% (95% CI: 0.6 to 3.0%) for patients receiving weight-adjusted dosing compared to 2.3% (95% CI: 1.1% to 3.9%) for those receiving standard doses of heparin products.
Adjusting the dose of heparin products for thromboprophylaxis post-bariatric surgery seems to be associated with a lower rate of in hospital VTE compared to a strategy of not adjusting the dose, although this did not reach statistical significance. This practice does not lead to an increase in adverse major bleeding events.
肥胖症手术人群是静脉血栓栓塞(VTE)的高危人群。目前尚不清楚标准(即未调整)剂量的低分子量肝素或普通肝素进行血栓预防,能否为接受肥胖症手术的肥胖患者提供足够的保护,或者是否需要更高剂量。我们试图确定基于体重的血栓预防给药方案对接受肥胖症手术的肥胖患者术后是否安全有效。
采用医学主题词表(MEDLINE)、医学与健康领域数据库(EMBASE)、Cochrane对照试验注册库以及所有循证医学综述进行系统的文献检索策略。计算不同结局的合并比例。
系统评价共纳入6项研究(1项随机对照试验、4项队列研究和1项半实验性试验),包含1858例患者。接受体重调整预防剂量肝素产品的肥胖症手术后患者,住院期间VTE发生率为0.54%(95%可信区间:0.2%至1.0%),而未进行体重调整剂量的患者为2.0%(95%可信区间:0.1%至6.4%)。两组大出血发生率相似:接受体重调整剂量的患者为1.6%(95%可信区间:0.6%至3.0%),接受标准剂量肝素产品的患者为2.3%(95%可信区间:1.1%至3.9%)。
与不调整剂量的策略相比,肥胖症手术后调整肝素产品预防血栓形成的剂量,似乎与较低的住院VTE发生率相关,尽管这未达到统计学显著性。这种做法不会导致严重不良出血事件增加。